JP6753843B2 - 改善されたポリエチレンイミンポリエチレングリコールベクター - Google Patents

改善されたポリエチレンイミンポリエチレングリコールベクター Download PDF

Info

Publication number
JP6753843B2
JP6753843B2 JP2017512466A JP2017512466A JP6753843B2 JP 6753843 B2 JP6753843 B2 JP 6753843B2 JP 2017512466 A JP2017512466 A JP 2017512466A JP 2017512466 A JP2017512466 A JP 2017512466A JP 6753843 B2 JP6753843 B2 JP 6753843B2
Authority
JP
Japan
Prior art keywords
polyplex
peg
lpei
cancer
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017512466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521090A (ja
JP2017521090A5 (enExample
Inventor
レビツキ、アレックス
ジュブラン、サリム
シル、アレクセイ
ジグラー、マヤ
タルハミ、アラー
ラングット、ヤエル
Original Assignee
タルグルムーネ セラピウティクス エージー
タルグルムーネ セラピウティクス エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タルグルムーネ セラピウティクス エージー, タルグルムーネ セラピウティクス エージー filed Critical タルグルムーネ セラピウティクス エージー
Publication of JP2017521090A publication Critical patent/JP2017521090A/ja
Publication of JP2017521090A5 publication Critical patent/JP2017521090A5/ja
Priority to JP2020139643A priority Critical patent/JP7406475B2/ja
Application granted granted Critical
Publication of JP6753843B2 publication Critical patent/JP6753843B2/ja
Priority to JP2023211790A priority patent/JP2024028995A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017512466A 2014-05-14 2015-05-14 改善されたポリエチレンイミンポリエチレングリコールベクター Active JP6753843B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020139643A JP7406475B2 (ja) 2014-05-14 2020-08-20 改善されたポリエチレンイミンポリエチレングリコールベクター
JP2023211790A JP2024028995A (ja) 2014-05-14 2023-12-15 改善されたポリエチレンイミンポリエチレングリコールベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993110P 2014-05-14 2014-05-14
US61/993,110 2014-05-14
PCT/IL2015/050514 WO2015173824A1 (en) 2014-05-14 2015-05-14 Improved polyethyleneimine polyethyleneglycol vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020139643A Division JP7406475B2 (ja) 2014-05-14 2020-08-20 改善されたポリエチレンイミンポリエチレングリコールベクター

Publications (3)

Publication Number Publication Date
JP2017521090A JP2017521090A (ja) 2017-08-03
JP2017521090A5 JP2017521090A5 (enExample) 2018-06-21
JP6753843B2 true JP6753843B2 (ja) 2020-09-16

Family

ID=54479412

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017512466A Active JP6753843B2 (ja) 2014-05-14 2015-05-14 改善されたポリエチレンイミンポリエチレングリコールベクター
JP2020139643A Active JP7406475B2 (ja) 2014-05-14 2020-08-20 改善されたポリエチレンイミンポリエチレングリコールベクター
JP2023211790A Pending JP2024028995A (ja) 2014-05-14 2023-12-15 改善されたポリエチレンイミンポリエチレングリコールベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020139643A Active JP7406475B2 (ja) 2014-05-14 2020-08-20 改善されたポリエチレンイミンポリエチレングリコールベクター
JP2023211790A Pending JP2024028995A (ja) 2014-05-14 2023-12-15 改善されたポリエチレンイミンポリエチレングリコールベクター

Country Status (16)

Country Link
US (4) US10278991B2 (enExample)
EP (1) EP3142673A4 (enExample)
JP (3) JP6753843B2 (enExample)
KR (2) KR102589295B1 (enExample)
CN (3) CN116966310A (enExample)
AU (2) AU2015260725B2 (enExample)
CA (1) CA2949017A1 (enExample)
IL (2) IL287206B2 (enExample)
MA (1) MA39970A (enExample)
MX (2) MX377654B (enExample)
NZ (1) NZ727092A (enExample)
PH (1) PH12016502258B1 (enExample)
RU (1) RU2771104C2 (enExample)
SG (2) SG10201911695SA (enExample)
WO (1) WO2015173824A1 (enExample)
ZA (1) ZA201608042B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771104C2 (ru) 2014-05-14 2022-04-26 Таргиммьюн Терапьютикс Аг Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
ES2755418T3 (es) 2015-11-17 2020-04-22 Bioncotech Therapeutics S L Novedosa composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina
AR107823A1 (es) * 2016-03-07 2018-06-06 Hanmi Pharm Ind Co Ltd Derivados de polietilenglicol y uso de los mismos
BR112019004017A2 (pt) 2016-09-04 2019-06-25 Targimmune Therapeutics Ag proteínas quiméricas para direcionar dsrna
ES2924138T3 (es) 2017-05-17 2022-10-04 Highlight Therapeutics S L Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina
CN111164093A (zh) * 2017-09-27 2020-05-15 塔尔格免疫治疗有限公司 去势抵抗性前列腺癌
JP2021516056A (ja) * 2018-03-08 2021-07-01 ターグイミューン セラピューティクス アーゲー 二本鎖ｒｎａ結合ドメインを含む組換えタンパク質
CN109893657B (zh) * 2019-02-28 2022-04-29 中国人民解放军军事科学院军事医学研究院 基因递送载体、药物复合物、抗肺纤维化药物及应用
MX2021011654A (es) * 2019-04-03 2022-02-21 Targimmune Therapeutics Ag Inmunoterapia para el tratamiento del cancer.
WO2020263782A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Methods and compositions for modifying nucleic acids and for killing cells
WO2021001023A1 (en) * 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
AU2021357354A1 (en) * 2020-10-08 2023-04-20 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
WO2023079142A2 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
US20240091348A1 (en) * 2022-09-20 2024-03-21 Highlight Therapeutics, S.L. Novel compositions based on polyinosinic-polycytidylic acid
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
KR20250106292A (ko) 2022-11-07 2025-07-09 타르그이뮨 테라퓨틱스 아게 폴리에틸렌이민 및 폴리에틸렌 글리콜을 포함하는 psma 표적화 선형 컨쥬게이트 및 이들을 포함하는 다중복합체
WO2024100046A1 (en) * 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59106279D1 (de) 1990-05-18 1995-09-21 Genentech Inc Neue protein-polykation-konjugate.
DE4104186A1 (de) 1991-02-12 1992-08-13 Genentech Inc Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DE19726186A1 (de) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
WO1999061032A1 (en) 1998-05-25 1999-12-02 Nippon Shinyaku Co., Ltd. Process for producing composite preparation containing nucleic acid
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20040043030A1 (en) 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
GB0119346D0 (en) 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US20040105839A1 (en) 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
WO2003072636A1 (en) 2002-02-28 2003-09-04 Jong Sang Park Cationic highly branched polyaminoester
EP1546173A4 (en) 2002-08-06 2006-05-31 Intradigm Corp METHOD FOR DOWNSTREGULATING THE EXPRESSION OF TARGET GENES IN VIVO BY INCLUDING INTERFERING RNA
AU2003279509A1 (en) * 2002-11-18 2004-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted double stranded rna mediated cell killing
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
WO2004087931A1 (en) 2003-04-03 2004-10-14 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050118718A1 (en) 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
WO2005090570A1 (en) 2004-03-24 2005-09-29 Supratek Pharma Inc. Therapeutic compositions and methods for treating diseases that involve angiogenesis
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CN101287500A (zh) * 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
US20090011004A1 (en) 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
JP2009523823A (ja) 2006-01-23 2009-06-25 アボット・ラボラトリーズ ｓｉＲＮＡ送達のための化学的に修飾されたポリカチオンポリマー
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CA2696627C (en) 2007-08-17 2016-09-27 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
ES2376175T3 (es) 2007-09-28 2012-03-09 Bind Biosciences, Inc. Direccionamiento a células de c�?ncer usando nanopart�?culas.
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
US20110027172A1 (en) 2007-12-10 2011-02-03 Zhuang Wang Drug delivery system for pharmaceuticals and radiation
WO2009086640A1 (en) 2008-01-10 2009-07-16 Nventa Biopharmaceuticals Corporation Adjuvant compositions comprising poly-ic and a cationic polymer
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
EP2113257A1 (en) 2008-04-30 2009-11-04 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer
EP2123304A1 (en) 2008-05-23 2009-11-25 Freie Universität Berlin Compounds suited as nanocarriers for active agents and their use
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010005740A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
DK2379597T3 (en) * 2008-12-22 2016-12-05 Alexander Levitzki Double-stranded RNA vector with EGFR as targets for SYSTEMIC CANCER TREATMENT
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
US20100266642A1 (en) 2009-02-20 2010-10-21 Bind Biosciences, Inc. Modified cells for targeted cell trafficking and uses thereof
US9603919B2 (en) 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
ES2368963B1 (es) 2009-07-04 2012-10-10 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado.
CN101638484A (zh) * 2009-08-24 2010-02-03 中国科学院长春应用化学研究所 聚乙二醇单甲醚-聚2-甲基-2-羧基碳酸丙烯酯接枝聚乙烯亚胺共聚物与制法及应用
CA2781717C (en) 2009-12-09 2017-09-12 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) complexes for delivery of interference rna
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
WO2011084521A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
EA201290497A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
ES2562817T3 (es) 2010-02-24 2016-03-08 Arrowhead Research Corporation Composiciones para el suministro dirigido de ARNip
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
WO2011130577A1 (en) 2010-04-14 2011-10-20 Intezyne Technologies, Incorporated Controlled polyplex assembly
EP2395041A1 (en) 2010-06-10 2011-12-14 F. Hoffmann-La Roche AG Polymers for delivery of nucleic acids
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
WO2012005572A1 (en) 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
FR2963350B1 (fr) 2010-07-30 2013-11-01 Univ D Evry Val D Essonne Nouveaux copolymeres a bloc et leurs utilisations pour delivrer une substance active dans une cellule.
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8461224B2 (en) 2011-03-04 2013-06-11 National Health Research Institutes Single monomer derived linear-like copolymer comprising polyethylenimine and poly(ethylene glycol) for nucleic acid delivery
US10029023B2 (en) 2011-03-31 2018-07-24 The Johns Hopkins University Theranostic imaging agents and methods of use
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
CN109481455A (zh) 2012-05-02 2019-03-19 箭头研究公司 治疗kras相关疾病的有机组合物
WO2014011053A1 (en) 2012-07-12 2014-01-16 Proqr Therapeutics B.V. Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell
CA2912975A1 (en) 2012-10-16 2014-04-24 William Marsh Rice University An improved nanovector based drug delivery system for overcoming drug resistance
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
KR102354613B1 (ko) 2012-11-15 2022-01-21 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
WO2014088087A1 (ja) 2012-12-06 2014-06-12 協和発酵バイオ株式会社 アジュバント用二重鎖リボ核酸
KR102285326B1 (ko) 2013-06-28 2021-08-04 에트리스 게엠베하 Rna를 세포에 도입하기 위한 조성물
CN104341488A (zh) 2013-08-02 2015-02-11 复旦大学 c(LyP-1)多肽及其构建的纳米递药系统和应用
US20160312218A1 (en) 2013-11-04 2016-10-27 Northeastern University System for co-delivery of polynucleotides and drugs into protease-expressing cells
CN105705143A (zh) 2013-11-08 2016-06-22 达娜-法勃肿瘤研究所公司 用于体内试剂递送的核酸纳米结构
MX378984B (es) 2014-03-14 2025-03-11 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso.
EP3126501A1 (en) 2014-03-24 2017-02-08 RiboxX GmbH Double-stranded rna conjugates and their use
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
RU2771104C2 (ru) 2014-05-14 2022-04-26 Таргиммьюн Терапьютикс Аг Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
EP3253414A4 (en) 2015-02-05 2018-07-11 The University Of Queensland Targeting constructs for delivery of payloads
WO2016183447A1 (en) 2015-05-14 2016-11-17 The Johns Hopkins University Compositions of nucleic acid-containing nanoparticles for in vivo delivery
ES2755418T3 (es) 2015-11-17 2020-04-22 Bioncotech Therapeutics S L Novedosa composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina

Also Published As

Publication number Publication date
IL248890B (en) 2021-10-31
CN106687121A (zh) 2017-05-17
WO2015173824A1 (en) 2015-11-19
AU2021203336B2 (en) 2024-11-07
US20190192563A1 (en) 2019-06-27
US20170072063A1 (en) 2017-03-16
ZA201608042B (en) 2018-11-28
MX2020012698A (es) 2021-02-15
RU2016146389A3 (enExample) 2018-12-26
EP3142673A4 (en) 2018-01-03
IL248890A0 (en) 2017-01-31
KR102472590B1 (ko) 2022-11-30
RU2771104C2 (ru) 2022-04-26
RU2016146389A (ru) 2018-06-15
IL287206B1 (en) 2023-10-01
MX2016014881A (es) 2017-05-01
MX377654B (es) 2025-03-11
AU2021203336C1 (en) 2025-05-08
JP2024028995A (ja) 2024-03-05
US11298376B2 (en) 2022-04-12
AU2015260725B2 (en) 2021-02-25
KR20220163536A (ko) 2022-12-09
SG10201911695SA (en) 2020-01-30
US10278991B2 (en) 2019-05-07
KR102589295B1 (ko) 2023-10-13
IL287206B2 (en) 2024-02-01
US20190262395A1 (en) 2019-08-29
IL287206A (en) 2021-12-01
NZ764423A (en) 2021-08-27
PH12016502258B1 (en) 2022-08-03
NZ727092A (en) 2021-07-30
JP2020196739A (ja) 2020-12-10
PH12016502258A1 (en) 2017-02-27
AU2015260725A1 (en) 2016-12-22
SG11201609442YA (en) 2016-12-29
US20220339189A1 (en) 2022-10-27
AU2021203336A1 (en) 2021-06-24
JP2017521090A (ja) 2017-08-03
US10543232B2 (en) 2020-01-28
MA39970A (fr) 2015-11-19
CN116966310A (zh) 2023-10-31
BR112016026581A2 (pt) 2017-10-31
KR20170005052A (ko) 2017-01-11
JP7406475B2 (ja) 2023-12-27
CA2949017A1 (en) 2015-11-19
CN116966311A (zh) 2023-10-31
EP3142673A1 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
JP7406475B2 (ja) 改善されたポリエチレンイミンポリエチレングリコールベクター
Veiseh et al. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells
US8497356B2 (en) Biomolecule polymer conjugates and methods for making the same
KR102052225B1 (ko) 관능성 pla-peg 공중합체, 그의 나노입자, 그의 제조법, 및 표적화 약물 전달 및 영상화를 위한 용도
JP2010504997A (ja) 核酸導入のための多機能性キャリアとその使用方法
WO2011072240A1 (en) Drug delivery of temozolomide for systemic based treatment of cancer
Wang et al. Double click-functionalized siRNA polyplexes for gene silencing in epidermal growth factor receptor-positive tumor cells
WO2019063705A1 (en) CANCER OF THE PROSTATE RESISTANT TO CASTRATION
CN107213468A (zh) 一种靶向纳米药物载体及其制备方法和应用
CN112088016A (zh) 含有多种活性剂分子的生物相容性共聚物
NZ764423B2 (en) Improved polyethyleneimine polyethyleneglycol vectors
BR112016026581B1 (pt) Poliplexo de um rna de fita dupla (dsrna) e um conjugado polimérico, uso do poliplexo e composições farmacêuticas que o compreendem
CN115461357A (zh) 用于递送药物活性剂的组合物和方法
Pan et al. Multifunctional water-soluble polymers for drug delivery
WO2024190929A1 (ja) タンパク質送達用ｐＨ応答性担体
中村雄太 Development of Extracellular and Intracellular Gene Delivery System for Cancer-selective Polymeric Nanocarrier
Christie Soluble and insoluble polymer delivery systems for cellular targeting and remote drug delivery

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200820

R150 Certificate of patent or registration of utility model

Ref document number: 6753843

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250